Neuland Laboratories LtdNSE: NEULANDLAB
Open the Neuland Laboratories Ltd page
Follow Neuland Laboratories LtdFree account. Get a note when Neuland Laboratories Ltd files.
Q1 FY27 results analysis · August 05, 2026

Neuland Laboratories Ltd (NEULANDLAB) Q1 FY27 Results Analysis: Revenue Surges 119%, Margin Above Sustainable Band

+962.4%PAT year on year, Rs. 147.67 Cr
Cofacto ResearchPublished August 05, 20262 min readPositive read
Quick summary

Neuland Laboratories Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 641.58 Cr (+119.15% YoY) and PAT growth of +962.40% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 05, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 641.58 Cr (+119.15% YoY)
PAT (Q1)Rs. 147.67 Cr (+962.40% YoY)
EBITDA margin35.59% (+2150 bps YoY)
EPS (Q1)Rs. 115.10 (+962.79% YoY)
Market capRs. 25,582.96 Cr
CMPRs. 19,956.00

Quarter Snapshot

Neuland Laboratories reported a strong Q1 with revenue up 119% YoY to Rs.641.58 Cr and EBITDA margin of 35.59%, above its sustainable 25-30% band. The growth is driven by CDMO exports to Europe and USA, with export share rising to 87%. Capacity expansions at Unit 1 and a strategic collaboration with Gland Pharma support future growth. However, sequential revenue declined 17% from Q4's record, and India domestic API business contracted, highlighting lumpiness.

Key Investment Insights

Key Positives

  • Revenue grew 119% YoY to Rs.641.58 Cr, the second-highest quarterly figure ever reported.
  • EBITDA margin (management definition) came in at 35.59%, above the guided 25-30% sustainable band.
  • PAT grew 962% YoY to Rs.147.67 Cr, with EPS at Rs.115.10.
  • Europe revenue surged 221% YoY and USA revenue grew 204% YoY, driving the CDMO-led growth.
  • Export revenue now constitutes 87% of total revenue, up from 66% in Q1FY26.
  • Two capacity expansions at Unit 1 (total Rs.183.2 Cr) approved to address near-full utilization.

Risk Factors

  • Revenue declined 17.35% QoQ from Q4 FY26's record Rs.776.25 Cr, consistent with management's warning about lumpy business.
  • India revenue declined 15.83% YoY to Rs.83.26 Cr, indicating domestic generic API contraction.
  • USA revenue declined 36.34% QoQ, reflecting lumpy shipment patterns in North America.
  • Finance costs increased 52% YoY to Rs.6.97 Cr due to higher borrowings for capex.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.